United Bank Takes $1.26 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

United Bank purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, Holdings Channel reports. The fund purchased 14,621 shares of the medical equipment provider’s stock, valued at approximately $1,259,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in Zimmer Biomet during the fourth quarter valued at approximately $204,000. Sivia Capital Partners LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $232,000. Federated Hermes Inc. increased its holdings in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after acquiring an additional 1,202 shares during the last quarter. Cerity Partners LLC increased its holdings in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after acquiring an additional 37,116 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of Zimmer Biomet by 5.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 29,889 shares of the medical equipment provider’s stock valued at $2,726,000 after acquiring an additional 1,511 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.28% of the stock is currently owned by company insiders.

Zimmer Biomet Trading Up 1.5%

NYSE:ZBH opened at $100.65 on Thursday. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The firm has a market capitalization of $19.20 billion, a P/E ratio of 24.49, a P/E/G ratio of 2.70 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The business has a 50 day simple moving average of $92.16 and a 200 day simple moving average of $90.85.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the prior year, the business earned $2.07 EPS. The firm’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were given a dividend of $0.24 per share. The ex-dividend date was Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ZBH shares. Citigroup reduced their price objective on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Canaccord Genuity Group increased their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Truist Financial raised their price target on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Zacks Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, July 27th. Finally, Wells Fargo & Company lowered their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.